Which is the most common adverse effect encountered during the first month of standard MDT (rifampicin + dapsone + clofazimine) in a patient with lepromatous leprosy?

Explanation

## Adverse Effects During MDT Initiation ### Most Common Complication: Lepra Reactions **Lepra reactions** are the most frequent adverse clinical events during MDT, occurring in **50–60% of BL/LL patients** within the first few months of treatment, often within the first 4 weeks. ### Types of Lepra Reactions | Type | Mechanism | Timing | Features | Management | | --- | --- | --- | --- | --- | | **Type 1 (Reversal Reaction)** | Delayed-type hypersensitivity (Type IV) to *M. leprae* antigens | During or after MDT | Inflammation in existing lesions, neuritis, iritis | Corticosteroids (prednisolone) | | **Type 2 (ENL)** | Immune complex deposition (Type III) | During or after MDT (especially LL/BL) | Painful nodules, fever, iritis, neuritis | Thalidomide or corticosteroids | ### Key Point: **Lepra reactions are immunological phenomena**, not drug toxicity. They represent the host immune system responding to *M. leprae* antigens released during bacterial death. This is the **most common clinical complication** during the first month of MDT. ### High-Yield: - **Type 1 reaction**: Common in BL; manifests as acute inflammation of existing lesions and nerves - **Type 2 reaction (ENL)**: Specific to LL/BL; presents with systemic symptoms (fever, malaise) and painful subcutaneous nodules - **Both types can cause permanent nerve damage** if not managed promptly with immunosuppression ### Clinical Pearl: The occurrence of lepra reactions during MDT is a sign of **immune reconstitution** and is actually a favorable prognostic indicator. However, it requires immediate recognition and treatment to prevent disability. ### Mnemonic: **LEPRA** — **L**ate hypersensitivity (Type 1) + **E**rythema nodosum-like (Type 2/ENL) + **P**ancreatic/systemic + **R**eaction + **A**cute inflammation ### Warning: ~~Hepatotoxicity~~ is a potential but **less common** adverse effect (1–2% incidence) and typically develops after weeks to months, not immediately. ~~Peripheral neuropathy~~ from the disease itself is chronic and progressive, not an acute adverse effect of MDT initiation.